Pacira Pharmaceuticals, Inc. Reports First Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Pacira Pharma (PCRX) Reports In-Line Q1 EPS
May 3, 2018 8:06 AM EDTPacira Pharma (NASDAQ: PCRX) reported Q1 EPS of $0.02, in-line with the analyst estimate of $0.02. Revenue for the quarter came in at $74.6 million versus the consensus estimate of $73.69 million.
Pacira reiterated its full year 2018 financial guidanceFor earnings history and earnings-related data on Pacira Pharma (PCRX) click here.
... More